BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal

 
• By Alaric DeArment
  
Cancer - DNA - test tube
BMS signed a deal with Volastra focused on synthetic lethality in oncology • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category